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Children with B-cell non-Hodgkin lymphoma (B-NHL) have an excellent chance of survival, however, current clinical risk
stratification places as many as half of patients in a high-risk group receiving very intensive chemo-immunotherapy. TP53
alterations are associated with adverse outcome in many malignancies; however, whilst common in paediatric B-NHL, their utility as
a risk classifier is unknown. We evaluated the clinical significance of TP53 abnormalities (mutations, deletion and/or copy number
neutral loss of heterozygosity) in a large UK paediatric B-NHL cohort and determined their impact on survival. TP53 abnormalities
were present in 54.7% of cases and were independently associated with a significantly inferior survival compared to those without a
TP53 abnormality (PFS 70.0% vs 100%, p < 0.001, OS 78.0% vs 100%, p= 0.002). Moreover, amongst patients clinically defined as
high-risk (stage III with high LDH or stage IV), those without a TP53 abnormality have superior survival compared to those with TP53
abnormalities (PFS 100% vs 55.6%, p= 0.005, OS 100% vs 66.7%, p= 0.019). Biallelic TP53 abnormalities were either maintained
from the presentation or acquired at progression in all paired diagnosis/progression Burkitt lymphoma cases. TP53 abnormalities




Current treatments for high-grade paediatric B-cell non-Hodgkin
lymphoma (B-NHL) in resource-rich countries are extremely
effective, with over 93% of children being cured [1–5]. Following
the recent demonstration of the benefit of the anti-CD20
monoclonal antibody rituximab, these same rates of cure are
now achieved even in patients presenting with established high-
risk clinical features (high lactate dehydrogenase (LDH), bone
marrow (BM) and/or central nervous system (CNS) disease) [5].
This success, however, has required the use of intensive multi-
agent chemo-immunotherapy regimens, associated with signifi-
cant, predominantly acute, toxicity such as infection and mucositis
as well as a small risk of long-term neurological side effects and
second malignancy [6–8]. Accordingly, reduction in treatment
intensity for at least some patients is a key objective. Unfortu-
nately, previous attempts to reduce treatment intensity in high-
risk bone marrow/CNS-positive patients resulted in unacceptable
deterioration in survival, highlighting the need for biomarker-
driven risk stratification to complement currently established
clinical and laboratory risk features [2, 9].
In contrast to the excellent overall survival currently achieved,
the outcome for children with primary refractory or relapsed
B-NHL is extremely poor, with fewer than 30% successfully
salvaged despite the routine use of high-dose chemotherapy
and stem cell rescue [10–13]. Mounting toxicity in this heavily pre-
treated group means that escalating intensity alone cannot
provide the solution to improving outcome in these patients
[14]. Instead, a more comprehensive understanding of the
biological drivers of therapy resistance is essential to support
the development of more effective and less toxic targeted
therapies for this group of patients [15].
Genomic studies have greatly improved our understanding of
the pathogenesis and clinically relevant heterogeneity of both
Burkitt lymphoma (BL) and diffuse large B cell lymphoma (DLBCL)
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[16–28]. Amongst their findings is the frequent mutation in both
diseases of the tumour suppressor gene TP53, inactivation of which
has an established role in lymphomagenesis [29–33]. TP53mutation,
often accompanied by loss of heterozygosity, is present in 25–50%
of sporadic BLs and approximately 20% of adult DLBCLs at
diagnosis, while a recent report suggested a lower incidence
amongst paediatric large B-cell lymphomas [16–22, 24–28, 34–36].
Consistently, TP53 mutations have been shown to be associated
with adverse clinical outcomes in adult aggressive B-cell lymphoma,
including DLBCL, and other lymphoid neoplasms [24, 34–38]. In
chronic lymphocytic leukaemia (CLL), they are associated with a
poor response to chemotherapy and detection of TP53 mutation
and 17p deletion is used to guide therapeutic decisions [39].
However, to date, no study has incorporated analysis of clinical
outcome with a detailed characterisation of TP53 alterations in
paediatric B-NHL where BL predominates, and the potential utility of
TP53 status as a clinical risk stratifier in this age group has remained
unclear.
To address this question, we collected and analysed a clinically
annotated cohort of 95 paediatric B-NHL patients from the UK. Using
sequencing and copy number (CN) microarray data we show that
TP53 abnormalities at presentation are associated with disease
progression and poor outcome. Importantly, the absence of TP53
abnormalities is associated with an extremely low risk of relapse even
in high-risk patients defined by high tumour stage and LDH.
Moreover, we demonstrate that biallelic TP53 abnormalities are either
maintained or acquired at the time of disease progression, implicating
loss of TP53 function in the development of treatment resistance.
Finally, we show that TP53 abnormalities are associated with complex
chromosomal copy number profiles, identifying a potential mechan-
ism underlying the evolution of the chemo-resistant disease.
METHODS
Patients and clinical samples
B-NHL samples from UK hospitals registered with the Children’s Cancer
and Leukaemia Group (CCLG) Tissue Bank between 1993 and 2014 were
obtained following informed consent from participants or their parent/
guardian. A minimum of three-years follow-up was obtained for all
survivors. Lymphomas were re-classified according to the World Health
Organisation (WHO) Classification of Tumours of Haematopoietic and
Lymphoid Tissues [40]. IG-MYC status was confirmed by fluorescence in situ
hybridisation (FISH) as described in Supplementary methods. The cohort
comprised BL (n= 64), DLBCL (n= 19), Burkitt-like lymphoma with 11q
aberration (BLL-11q, n= 5) and remaining cases which could not be fully
classified (B-NHL, NOS n= 7).
TP53 mutation and 17p copy number analysis
TP53mutational status was assessed using whole-exome sequencing (WES,
n= 90) or Sanger sequencing of exons 5 to 8 (n= 5). WES data were
generated using Illumina Nextera Exome enrichment (n= 89) or TWIST
Human Core Exome kit (n= 1) and sequenced on an Illumina NovaSeq
within the Newcastle University Genomics Core Facility or Illumina HiSeq
by Eurofins Genomics (Germany). Data were analysed using the Genome
Analysis Toolkit (GATK 3.7) and variants called using Mutect2. PCR products
for Sanger sequencing were amplified using primers designed for TP53
(Supplementary Table 1) and sequenced by Eurofins Genomics. WES base
calls were confirmed by Sanger sequencing in 39 cases, with 100%
concordance between sequencing methods.
Copy number alterations (CNAs) of 17p and other chromosomes were
identified using Affymetrix Cytoscan HD, Genome-wide Human SNP Array
6.0 or OncoScan arrays performed by Eurofins Genomics. Raw data were
analysed and visualised in Nexus Copy Number 10.0 (BioDiscovery) to
detect CNAs and copy number neutral loss of heterozygosity (CNN-LOH) in
all samples.
Chromosomal complexity analysis. Complex patterns of chromosomal copy
number abnormality were defined as those with a fluctuation between two or
more copy number states involving two or more individual segments ≥100 kb
on a chromosome arm. These included chromothripsis-like patterns of
alternation between two copy number states as well as stepwise increase in
copy number of chromosome arms. This definition excludes regions with
heterozygous deletion followed by homozygous deletion, single regions of
gain, deletion or CNN-LOH, and abnormalities affecting alternate
chromosome arms.
Statistical analyses. Estimates of overall survival (OS) and progression-free
survival (PFS) were calculated and compared using Kaplan–Meier methods,
log-rank tests and Cox-regression models. OS was defined as the time from
diagnosis to death from any cause, with censoring at the date of the last
contact. PFS was defined as the date of diagnosis to the time of disease
progression or death. We report three-year OS and PFS survival rates. All
variables conformed to the proportional hazards assumption. Other compar-
isons were performed using Fisher’s exact test. Analyses were performed using
R Bioconductor packages ‘survival’ for univariate and multivariate analysis and
‘survminer’ for visualisation of Kaplan–Meier survival curves.
RESULTS
Patient demographics and clinical characteristics
The cohort consisted of the diagnostic tumour samples from 95
UK paediatric B-NHL patients. In total, 89 of the 95 (94%) cases
were uniformly treated on FAB/LMB96 protocols (trial or interim
guidelines) and had a complete follow-up with a median follow-
up of 66.2 months (1–270.4 months) (Table 1). In keeping with
previously published clinical trial cohorts [4, 41], the 89 FAB/
LMB96-treated cases in the present study demonstrated a median
age of 8 years, a male predominance of 3.4:1, a predominance
(67%) of Burkitt lymphoma, a majority of high stage (III/IV) patients
(73%), bone marrow disease in 18% and CNS disease in 6% of
cases. MYC status was available for 84/89 samples (five cases failed
FISH or had no available material), amongst which 63 (75%) had
an IG-MYC translocation, including 56/58 BL, 4/16 DLBCL, 3/5 B-
NHL, NOS and 0/5 BLL-11q cases. Survival estimates at three years
for PFS and OS were 83.1% (95% CI 75.7–91.3) and 87.6% (95% CI
81.1–94.8), respectively. For those patients with disease progres-
sion (primary refractory or relapsed disease), the median time
from the initial diagnosis to progression was 4.5 months (range
2.8–7.7 months). The additional 6 of the 95 cases (4 BL, 1 DLBCL
and 1 B-NHL, NOS) were included in the genomic analysis only.
Genomic analysis of the TP53 locus
TP53 mutations were found in 46/95 (48.4%) cases: 37 cases had a
single non-synonymous somatic mutation, eight had two different
somatic mutations and one had a germline mutation (DLBCL with Li-
Fraumeni syndrome) (Fig. 1A, Supplementary Table 2). TP53mutations
were found in 37/64 (57.8%) BL, 4/19 (21.0%) DLBCL, 4/7 (57.1%) B-
NHL, NOS cases and 1/5 (20.0%) BLL-11q cases. All three DLBCL cases
with somatic TP53 mutations and all four mutated B-NHL, NOS cases
carried IG-MYC rearrangements. The 35 distinct mutations included 33
missense mutations and two deletions leading to frameshifts. All but
two mutations involved the DNA binding domain and experimental
data from the UMD and IARC TP53 databases showed all but two of
the mutations to be functionally deleterious [42, 43]. As seen in other
cancers [42, 44], the most commonly mutated residues were R175 (n
= 6), G245 (n= 5), R248 (n= 7) and R273 (n= 4).
Next, we analysed 17p copy number alteration and identified
deletions in 15/95 (15.8%) cases: 10/64 (15.6%) BL, 4/19 (21.0%)
DLBCL and 1/7 (14.3%) B-NHL, NOS. The median region of deletion
was 20.6 Mb (range 17.9–22.2 Mb), resulting in deletion of >80% of
17p (Fig. 1B). Additionally, 8/95 cases (8.4%) showed CNN-LOH: 7/
64 (10.9%) BL and 1/19 (5.3%) DLBCL. The median region of CNN-
LOH was 19.5 Mb (range 12.9–22.3 Mb), again covering >80% of
17p (Fig. 1C). All 17p deletions and CNN-LOH involved the TP53
locus. The presence or absence of TP53 copy number deletion was
assessed by FISH in 76/95 cases: 49/64 BL, 16/19 DLBCL, 5/5 BLL-
11q and 6/7 B-NHL, NOS (Supplementary Table 2). These included
12/15 cases with TP53 deletion, 5/8 with CNN-LOH and 59/72 with
neither. In each case, the FISH results were concordant with the
copy number array findings.















Combining the mutation and CN data for the TP53 locus
showed that abnormalities are common at presentation with 52/
95 (54.7%) cases harbouring at least one abnormality and
functionally inactivating biallelic events present in 26/95 (27.4%)
cases (Fig. 1D; Supplementary Table 2). Of the 26 cases with
monoallelic TP53 abnormalities, 20 had a single somatic hetero-
zygous mutation (median variant allele frequency 39%, range
18–50%), four had a deletion and two had CNN-LOH. Among the
26 cases with biallelic abnormalities, 17 had TP53 mutation
together with a deletion or CNN-LOH, two had a homozygous
mutation and seven had compound heterozygous mutations. The
correlation between p53 protein expression and TP53 status was
assessed by p53 immunohistochemistry (IHC) in a subset of cases.
In most cases, TP53 mutation was associated with overexpression
of p53 protein but the correlation between p53 expression levels
and TP53 status was variable and IHC could not reliably detect the
range of genomic alterations (Supplementary Table 3).
TP53 abnormalities are associated with chromosomal
complexity
Genomic TP53 alterations have been associated with genomic
complexity in DLBCL and other tumours [21, 33, 44–46]. In this
study, TP53 abnormalities were not associated with the number of
CNAs or the percentage of genome altered (Supplementary
Table 4). However, TP53 abnormalities were associated with
complex CN profiles of specific chromosomes. (Fig. 2; Supple-
mentary Table 5). Excluding BLL-11q, which is defined by a
complex 11q rearrangement, chromosomes with complex CNAs
were present in 30/51 cases with TP53 abnormality but only in 5/
39 cases with wild-type TP53 (p < 0.001). This association was
particularly strong for BL, in which 24/40 (60%) TP53 abnormal
cases harboured a complex chromosome compared to only 1/24
(4.2%) TP53 wild-type cases (p= 0.001). The Li-Fraumeni syndrome
case (DLBCL with TP53 biallelic abnormality) demonstrated the
highest number of complex CNAs within the whole cohort, but
otherwise there was no association between TP53 abnormalities
and complex CNAs in DLBCL cases.
Most notably, complex CNAs of 1q, 11q and 13q were
associated with biallelic TP53 abnormalities (p < 0.05) (Fig. 2).
Complexity of 1q typically involved stepwise increases in copy
number, with only two cases having telomeric deletion (Supple-
mentary Fig. 1). Both chromosome arms 11q and 13q recurrently
showed a pattern of a region of gain adjacent to telomeric
deletion, similar to the profile defining BLL-11q cases [47]
(Supplementary Figs. 2–3). All ten cases with this characteristic
gain-telomeric deletion pattern of 13q (here termed 13qplex) were
BL (Supplementary Table 5). The MIR17HG locus mapped within
the region of 13q CN gain/amplification, notably located in the
highest peak for 9/10 (90%) 13qplex cases (Supplementary Fig. 3).
Survival analysis of TP53 abnormalities in paediatric B-NHL
The clinical characteristics of cases with or without a TP53
abnormality are presented in Supplementary Table 6. Univariate
survival analyses identified a significantly adverse PFS for patients
with high disease stage, bone marrow involvement or high LDH
(Supplementary Table 7). CNS involvement was associated with a
hazard ratio of 3.0 but did not reach significance, likely due to the
low number of cases (n= 5). Those with mutations had significantly
inferior three-year survival compared to those without (PFS 66.7%
(95% CI 54.2–82.0) vs 100% (95% CI 100–100), p < 0.001 and OS
75.6% (95% CI 64.0–89.2) vs 100% (95% CI 100–100), p < 0.001)
(Supplementary Fig. 4A, B), although no hazard ratio could be
reported due to the absence of events in cases without TP53
mutation. Likewise, 17p CNN-LOH involving TP53 was also
associated with worse outcome (PFS HR 4.9 (95% CI 1.6–15.6),
p= 0.007; OS HR 4.7 (95% CI 1.2–17.7), p= 0.023) (Supplementary
Fig. 4C, D, Supplementary Table 7). In contrast, as previously
reported in the context of the FAB/LMB96 trial, univariate analysis
Table 1. Clinical and cytogenetic characteristics of the FAB/LMB96-




Diagnosis BL 60 (67.4%)
DLBCL 18 (20.2%)
BLL-11q 5 (5.6%)
B-NHL, NOS 6 (6.7%)
Median age at diagnosis (range), years 8 (0.5–17)
Sex Male 68 (76.4%)
Female 20 (22.5%)
Not available 1 (1.1%)
Tumour stage Stage I or II 24 (27.0%)
Stage III or IV 65 (73.0%)
Not available 0 (0.0%)
BM involvement Y 16 (18.0%)
N 71 (79.8%)
Not available 2 (2.2%)
CNS involvementa Y 5 (5.6%)
N 83 (93.3%)
Not available 1 (1.1%)
LDH > 2x ULN Y 38 (42.7%)
N 38 (42.7%)
Not available 13 (14.6%)
MYC translocation Y 63 (70.7%)
N 21 (23.6%)
Not available 5 (5.6%)
Risk Group High 41 (46.1%)
Intermediate 38 (42.7%)
Low 4 (4.5%)
Not available 6 (6.7%)
Treatment Group Group A 4 (4.5%)
Group B 68 (76.4%)
Group C 15 (16.9%)
Group unknown 2 (2.2%)
Rituximab addedb 2 (2.2%)
No Rituximab 84 (94.4%)
Rituximab unknown 3 (3.4%)
Outcome
PFS Progression/relapse 15 (16.9%)
Median time to event
(range), months
4.5 (0.9–7.7)
OS Deaths 11 (12.4%)
Median time to death
(range), months
6.5 (0.9–11.1)
BL Burkitt lymphoma, DLBCL diffuse large B-cell lymphoma, BLL-11q Burkitt-
like lymphoma with 11q aberrations, B-NHL, NOS B-cell non-Hodgkin
lymphoma not otherwise specified, Y Yes, N No, “-“ no event, hazard ratio
not reported, BM bone marrow, CNS central nervous system, CSF
cerebrospinal fluid, LDH lactate dehydrogenase, ULN upper limit of normal,
PFS progression-free survival, OS overall survival.
aOne case had CSF involvement.
bTwo cases received rituximab from the start of first-line therapy, two other
patients received rituximab following switch to group C therapy following
post-CYM-1 reassessment.
A.M. Newman et al.
3
Leukemia
showed that, agnostic of TP53 mutation status, cases with deletion
of 17p including the TP53 locus did not have inferior outcome
(Supplementary Fig. 4E, F, Supplementary Table 7) [2].
Combining the TP53 locus alterations (Fig. 3A), patients with at
least one TP53 abnormality had a significantly inferior 3-year
survival compared to those with no abnormality (PFS 70.0% (95%
CI 58.4–83.9) vs 100 (95% CI 100–100), p < 0.001 and OS 78.0%
(95% CI 67.3–90.4) vs 100 (95% CI 100–100), p= 0.002) (Fig. 3B, C).
Importantly, those patients without any TP53 abnormality at initial
diagnosis had a PFS of 100% (95% CI 100–100) and an OS of 100%
(95% CI 100–100). Most TP53 abnormalities were seen in patients
diagnosed with BL and the presence of any TP53 abnormality
remained adversely prognostic within this subgroup (PFS 67.5%
(95% CI 54.4–83.7) vs 100% (95% CI 100–100), p= 0.005 and OS:
75% (95% CI 62.7–89.7) vs 100 (95% CI 100–100, p= 0.017)
(Supplementary Fig. 5). Both monoallelic and biallelic TP53
abnormalities were associated with adverse outcome, when
compared with TP53 wild-type cases (monoallelic PFS 76.0%
(95% CI 61.0–94.7) vs 100% (95% CI 100–100), p= 0.001 and OS
80.0% (95% CI 65.8–97.3) vs 100% (95% CI 100–100), p= 0.004;
biallelic PFS 64.0% (95% CI 47.7–85.9) vs 100% (95% CI 100–100),
p < 0.001 and OS 76.0% (95% CI 61.0–94.7) vs 100 (95% CI
100–100) p= 0.001), but with no significant difference identified
between these two groups (Fig. 3D, E). There was no association
between prognosis and either complex CNA patterns of 1q, 11q or
13q (Supplementary Table 8) or gain of MIR17HG. Neither was
there a difference in outcome for patients with or without any
complex CNA (PFS HR 1.7 (95% CI 0.6–4.7), p= 0.295; OS HR 1.8
(95% CI 0.5–5.9), p= 0.332).
Multivariate analysis was performed to assess the impact of
TP53 abnormalities alongside established high-risk clinical factors
(BM and CNS involvement, stage and high LDH) (Supplementary
Table 7). Due to the lack of an event amongst the TP53 wild-type
patients included in this analysis, we are unable to report a hazard
ratio for TP53 status; however, having included this strong
prognostic factor in the model, those established high-risk clinical
factors were not independently significant.
TP53 status risk stratifies patients with clinically defined high-
risk disease
The Inter-B-NHL ritux 2010 trial (NCT01516580) has recently
demonstrated the survival benefit of adding rituximab to modified
FAB/LMB96 chemotherapy for patients with high-risk disease
(stage III and LDH > 2x ULN, stage IV or Burkitt leukaemia) [5].
Nevertheless, rituximab-chemotherapy was associated with
increased incidence of prolonged hypogammaglobulinaemia
Fig. 1 TP53 mutations and genomic copy number abnormalities are detected in a high proportion of paediatric B-NHL cases. (A) A
lolliplot showing 53 somatic and one germline mutation (R248Q detected in a Li-Fraumeni syndrome case). (B) Deletion of the TP53 locus was
detected in 3/14 patients with disease progression (P) and 12/78 with no disease progression (NP). (C) CNN-LOH of the TP53 locus was
detected in 5/14 patients with disease progression (P) and 3/78 with no disease progression (NP). (D) Representation of co-occurrence of TP53
abnormalities. Inner circle represents TP53 copy number status; outer ring represents TP53 mutation status.
A.M. Newman et al.
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and may be associated with a greater number of infections [5].
Given the inferior outcome of these patients prior to the use of
rituximab and the unacceptable deterioration in that outcome
with a previous attempt to reduce therapy intensity [9], they
represent a key group for further biomarker-driven stratification.
Therefore, we sought to understand the prognostic impact of TP53
abnormalities specifically in this group. High-risk patients had a
higher rate of TP53 abnormality (27/41, 66%) than low/inter-
mediate-risk groups (20/42, 48%), but here this association was
specifically within the TP53 biallelic group (p= 0.037)
Fig. 3 Identification of patient risk groups based on TP53 status. (A) Oncoplot showing TP53 status with clinical and molecular parameters
as described in the key. Data is plotted from left to right according to TP53 status. Kaplan–Meier plots showing (B) progression-free and (C)
overall survival for any TP53 abnormality (deletion, CNN-LOH and/or mutation), and (D) progression-free and (E) overall survival according to
normal (green), monoallelic (amber) or biallelic (red) TP53 status. # Li-Fraumeni syndrome case.
Fig. 2 A pattern of complex chromosomal abnormalities in paediatric B-NHL is associated with TP53 status. Oncoplot showing TP53 status
(upper panel) and associated complex chromosomes (lower panel). Histogram displaying the frequency of complex abnormalities of each
chromosome arm in biallelic, monoallelic and TP53 normal groups. As a diagnosis of BLL-11q is determined by the presence of a complex 11q
rearrangement, these five cases were excluded from this analysis. TP53 Biallelic with 1q complexity vs TP53 Normal with 1q complexity, p= 0.026;
TP53 Biallelic with 11q complexity vs TP53 Normal with 11q complexity, p= 0.006. TP53 Biallelic with 13q complexity vs TP53 Normal with 13q
complexity, p= 0.001; TP53 Biallelic with 13q complexity vs TP53 Monoallelic with 13q complexity, p= 0.002. Fisher’s Exact test *= p < 0.05, **= p
< 0.01; # Li-Fraumeni syndrome case.
A.M. Newman et al.
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(Supplementary Table 6). As expected, the high-risk group had an
inferior survival compared to the intermediate and low-risk groups
(PFS 70.7% (95% CI 58.1–86.1) vs 94.7% (95% CI 87.9–100.0) vs
100.0% (95% CI 100.0–100.0), p= 0.013) and OS 78.6% (95% CI
66.4–91.8) vs 94.7% (95% CI 87.9–100.0) vs 100.0% (95% CI
100.0–100.0), p= 0.067) (Fig. 4A, B). Strikingly, despite the
substantial clinical value of stage and LDH, the absence of any
TP53 abnormality in high-risk patients remained strongly asso-
ciated with an excellent clinical outcome compared to high-risk
patients with any TP53 abnormality (PFS 100% (95% CI 100–100)
vs 55.6% (95% CI 39.7–77.9), p= 0.005 and OS 100% (95% CI
100–100) vs 66.7% (95% CI 51.1–87.0), p= 0.019) (Fig. 4C, D).
Stratification of the low/intermediate-risk group identified an
inferior outcome for patients with any TP53 abnormality but this
did not reach significance (PFS 100 % (95% CI 100–100) vs 90%
(95% CI 77.8–100%) vs, p= 0.133 and OS 100% (95% CI 100–100)
vs 90% (95% CI 70.7–100%), p= 0.133) (Supplementary Fig. 6).
Biallelic TP53 abnormalities evolve during disease progression
Very little is known about the genomic changes associated with
therapy resistance and disease progression in BL or other
paediatric B-NHL [48]. To understand the evolution of TP53
abnormalities associated with therapy resistance we investigated
the paired biopsies taken at the time of disease progression for 7
cases and one further paired biopsy (patient BL39) taken from a
viable residual tumour mass detected at routine reassessment
following the CYM-1 component of FAB/LMB96 therapy. Amongst
six BL cases, four had major clonal biallelic TP53 abnormalities at
the time of the original diagnosis (Fig. 5 and Supplementary
Table 9) and these same biallelic abnormalities were maintained at
the time of disease progression. Interestingly, the other two BL
cases showed acquisition of biallelic TP53 abnormalities in the
second biopsies, further supporting a role for TP53 in treatment
resistance. The first, BL23, had only a monoallelic clonal G245S
mutation at diagnosis but developed CNN-LOH at relapse,
rendering this mutation biallelic. The other, BL39, lacked a
detectable TP53 abnormality at initial diagnosis but the residual
tumour had both a deletion of chromosome 17p and a classical
pathogenic R248W mutation. Analysis of WES data failed to
identify even a minor clonal R248W mutation at presentation (0/
124 reads). In contrast to the BL cases, both DLBCL cases with
paired material harboured a monoallelic TP53 abnormality at both
diagnosis and progression. In five of the six BL cases, the therapy-
resistant disease was associated with an increase in the number of
chromosomes showing a complex copy number profile (Fig. 5).
DISCUSSION
The addition of rituximab to first-line therapy for children with
high-risk B-NHL has resulted in ≥93% event-free survival (EFS) in
all risk groups [5]. This success requires intensive multi-agent
chemotherapy and comes at the cost of significant acute toxicity
and there now exists a growing understanding of the long-term
sequelae [6–8]. However, with very few relapse events occurring,
identifying the prognostic biomarkers required for improved risk
stratification in this rare patient group has become extremely
challenging. Consequently, we undertook an analysis of the
prognostic significance of TP53 status in a large national cohort of
paediatric mature B-NHL cases diagnosed prior to the routine
introduction of rituximab therapy. This showed that the presence
or absence of TP53 abnormalities defines two patient groups with
markedly different progression-free and overall survival rates,
adverse and favourable respectively.
The principal clinical challenges in paediatric B-NHL have, for
some years, been: (1) improving survival in high-risk patients; (2)
reducing therapy intensity without increasing risk of relapse [9]; (3)
identifying mechanisms of therapy resistance which result in
extremely poor survival following relapse. Addressing the first of
these challenges, the international collaborative trial Inter-B-NHL
ritux 2010 (NCT01516580) recently demonstrated an 11% increase
in EFS in high-risk patients (defined as stage III with LDH greater
than twice the upper limit of normal, stage IV or Burkitt leukaemia)
with the addition of six doses of rituximab to a modified FAB/
LMB96 chemotherapy schedule [5]. This contrasts with the
Fig. 4 TP53 status differentiates patients in the clinically defined high-risk group in paediatric B-NHL. Kaplan–Meier plots showing (A)
progression-free and (B) overall survival for high, intermediate and low clinical risk groups, and (C) progression-free and (D) overall survival in
high-risk patients according to the presence of any TP53 abnormality.
A.M. Newman et al.
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unacceptable reduction in survival seen in high-risk bone marrow/
central nervous system positive patients randomised to reduced
intensity therapy within the FAB/LMB96 study [9]. Nevertheless,
within the reduced intensity arm of the high-risk FAB/LMB96 study,
an 80% EFS was seen, implying that only a minority of patients
benefit from intensification of treatment. The inability to identify
those with a low risk of treatment failure has hampered risk
stratification beyond clinicopathological features. Here, we show
that within the high-risk patient group, (as defined in the Inter-B-
NHL trial), TP53 wild-type patients have a very low risk of relapse,
despite the absence of rituximab therapy. If validated in interna-
tional trial cohorts, analysis of TP53 status may allow identification
of a subset of patients currently considered high-risk for whom
chemo-immunotherapy can be de-intensified without compromis-
ing efficacy. Initially, this could involve omitting rituximab but
further reduction in chemotherapy similar to that attempted within
FAB/LMB96, could also be considered. Our finding provides a
potential biomarker platform for future trials of therapy reduction,
albeit that a large number of patients and a more effective salvage
strategy would be necessary for such a trial.
Critical to the better treatment of progressive or relapsed
disease is a much deeper understanding of the drivers of therapy
resistance. The finding that TP53 abnormalities are associated with
increased risk of disease progression, and our analysis of paired
Burkitt lymphoma samples showing that all cases either main-
tained or developed biallelic TP53 abnormalities at progression,
suggest a key role for TP53 loss of function in this process. In
support of this assertion, Reutter et al. [49] found multiple TP53
abnormalities at diagnosis and relapse in each of the five relapsed
BL cases studied. Given the many biological pathways impacted
by p53, the mechanisms by which TP53 abnormalities promote
therapy resistance merits further investigation in support of
developing an effective salvage therapy. It is notable, therefore,
that we found a strong association between TP53 abnormalities
and MYC rearrangements in our cohort. Since these two cancer
genes cooperate to drive experimental lymphomagenesis in mice
and have been associated with a particularly poor prognosis when
concurrently mutated and translocated, respectively, in adult
DLBCL, a deeper mechanistic understanding of the interactions
between p53 and MYC in paediatric B-NHL may be particularly
informative in this regard [29, 32, 38].
Mutations, present in half of cases, were the most frequent TP53
abnormalities detected in our cohort. As expected, TP53 deletions
and CNN-LOH were less prevalent and were mostly present in
tumours with TP53 mutation [2, 50–53]. Overall, half of all cases
with a TP53 abnormality had biallelic alterations expected to
abrogate wild-type TP53 functions at diagnosis and biallelic events
were present in all BL tumours at the time of progression.
However, while the presence of any TP53 abnormality was
associated with an increased risk of disease progression and
death, there was no difference in PFS or OS between cases with
monoallelic or biallelic alterations at diagnosis. This contrasts with
recent findings in myelodysplastic syndrome and plasma cell
myeloma, in which specifically biallelic TP53 alterations at
diagnosis are associated with poor survival [54–56]. The increasing
evidence that many mutant p53 proteins exhibit gain of function
or dominant-negative properties may provide a partial explana-
tion but our analysis of paired diagnosis/progression BL samples
Fig. 5 Biallelic TP53 abnormalities are either maintained or acquired at the time of progression of BL. (A) Overview of clinical and
molecular parameters for seven patients with matched samples taken at initial diagnosis (D) and at the time of progression (P). (B) One patient
had matched samples from initial diagnosis and the time of reassessment.
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suggests the alternative explanation that clones/subclones with
monoallelic TP53 abnormalities may evolve to a biallelic state
during disease progression under the selective pressure of therapy
[32, 33, 57]. Interesting in this regard is the recent report of a case
of relapsed BL with the expansion of a low level (2% VAF) TP53
R248Q mutation at diagnosis to a 93% VAF at relapse, secondary
to a combination of clonal expansion and CNN-LOH [58].
TP53 mutations are associated with several types of genomic
instability, including aneuploidy and chromothripsis, and thus
increased genome complexity across the cancer spectrum
[33, 44, 46]. Notably, a recently described subset of adult DLBCL
carrying frequent biallelic inactivation of TP53 by mutation and
17p deletion is selectively associated with an increase in small and
large CNAs [21, 45]. Similarly, an association between TP53
abnormalities and chromothripsis-like changes, including of 13q,
has been reported in adult DLBCL [59, 60]. Although we did not
see an effect on global genomic complexity in our predominantly
BL paediatric cohort, we did observe the correlation of TP53
abnormalities with complex copy number patterns involving 1q,
11q and 13q. The 13q gains centred on the MIR17HG gene, in
keeping with a previous report of an association between 17p
deletion and MIR17HG gain in a small sample set [50]. That report
speculated that MIR17HG gain was associated with relapse but our
data suggest that this probably results indirectly from the
association of MIR17HG gain with TP53 abnormalities [50].
We have demonstrated the clinical importance of TP53
abnormalities in paediatric B-NHL, identifying them as a potential
biomarker capable of further risk-stratifying patients currently
considered high-risk. These findings now need to be validated in a
large international trial cohort. For those children without a TP53
abnormality, the risk of disease progression is extremely low and
stratified trials examining therapy reduction should be considered.
Evolution of biallelic abnormalities at relapse implicates TP53
biology as a driver of therapy resistance and relapse and further
understanding of the underlying mechanisms could lead to new
strategies to prevent or treat therapy-resistant disease.
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